AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 8316580 — intervention group
Group type: EXPERIMENTAL
Intervention: Passive hip extension stretching
Number of subjects: 25
Study 8316580 — intervention group
Group type: EXPERIMENTAL
Intervention: Trunk flexor exercises
Number of subjects: 25
Study 8316580 — intervention group
Group type: COMPARATOR
Intervention: Hip extension stretching or trunk flexor exercises
Number of subjects: 25
Study 2423806 — intervention group
Group type: EXPERIMENTAL
Intervention: Indoramin (50 mg t.i.d. per os)
Number of subjects: 20
Study 2423806 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 2423806 — intervention group
Group type: EXPERIMENTAL
Intervention: Indoramin
Number of subjects: 20
Study 31603262 — intervention group
Group type: EXPERIMENTAL
Intervention: Interval sprinting exercise (ISE)
Number of subjects: 60
Study 31603262 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 60
Study 28904068 — intervention group
Group type: EXPERIMENTAL
Intervention: Empagliflozin 10 mg
Number of subjects: 7020
Study 28904068 — intervention group
Group type: EXPERIMENTAL
Intervention: Empagliflozin 25 mg
Number of subjects: 7020
Study 28904068 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7020
Study 27170524 — intervention group
Group type: EXPERIMENTAL
Intervention: McKenzie method
Number of subjects: 70
Study 27170524 — intervention group
Group type: COMPARATOR
Intervention: Motor control exercises
Number of subjects: 70
Study 25801698 — intervention group
Group type: EXPERIMENTAL
Intervention: Eltrombopag treatment
Number of subjects: 117
Study 25801698 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 117
Study 23073712 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily home-based exercise programme and self-care (n=11)
Number of subjects: 23
Study 23073712 — intervention group
Group type: COMPARATOR
Intervention: Self-care measures alone (n=12)
Number of subjects: 23
Study 20813044 — intervention group
Group type: EXPERIMENTAL
Intervention: Story-based intervention for health communication
Number of subjects: 10
Study 20813044 — intervention group
Group type: EXPERIMENTAL
Intervention: Revised stories based on participant feedback
Number of subjects: 10
Study 20813044 — intervention group
Group type: EXPERIMENTAL
Intervention: Focus group evaluation of story booklets
Number of subjects: 10
Study 18204344 — intervention group
Group type: EXPERIMENTAL
Intervention: Quetiapine
Number of subjects: 22
Study 18204344 — intervention group
Group type: COMPARATOR
Intervention: Current treatment (Control)
Number of subjects: 22
Study 16600940 — intervention group
Group type: EXPERIMENTAL
Intervention: Yogurt-plus-quadruple therapy (AB-yogurt 400 mL/d for 4 weeks + quadruple therapy for 1 week)
Number of subjects: 138
Study 16600940 — intervention group
Group type: COMPARATOR
Intervention: Quadruple therapy only (without AB-yogurt)
Number of subjects: 138
Study 14967868 — intervention group
Group type: EXPERIMENTAL
Intervention: 75 g CHO as a glucose solution at 15 min before exercise (‐15 trial)
Number of subjects: 18
Study 14967868 — intervention group
Group type: EXPERIMENTAL
Intervention: 75 g CHO as a glucose solution at 75 min before exercise (‐75 trial)
Number of subjects: 18
Study 14967868 — intervention group
Group type: COMPARATOR
Intervention: 25 g CHO as a glucose solution 45 min before exercise
Number of subjects: 18
Study 14967868 — intervention group
Group type: COMPARATOR
Intervention: 200 g CHO as a glucose solution 45 min before exercise
Number of subjects: 18
Study 14967868 — intervention group
Group type: COMPARATOR
Intervention: Placebo 45 min before exercise
Number of subjects: 18
Study 14967868 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-exercise CHO ingestion (any amount)
Number of subjects: 18
Study 10977787 — intervention group
Group type: EXPERIMENTAL
Intervention: 1alphaD(2)
Number of subjects: 138
Study 10977787 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 138
Study 8770990 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 mg/day dose of anti-LFA1 monoclonal antibody (MoAb) with a loading dose of 30 mg
Number of subjects: 15
Study 8770990 — intervention group
Group type: EXPERIMENTAL
Intervention: Additional group receiving the same protocol (15 mg/day with a loading dose of 30 mg)
Number of subjects: 15
Study 1282180 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicorandil 20 mg b.i.d. for 4 weeks
Number of subjects: 129
Study 1282180 — intervention group
Group type: COMPARATOR
Intervention: Isosorbide-5-mononitrate (MN) 20 mg b.i.d. for 4 weeks
Number of subjects: 129
Study 1282180 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicorandil 10 mg t.i.d. for 2 weeks then 20 mg t.i.d. for 4 weeks
Number of subjects: 129
Study 1282180 — intervention group
Group type: COMPARATOR
Intervention: Isosorbide dinitrate (ISDN) 10 mg t.i.d. for 2 weeks then 20 mg t.i.d. for 4 weeks
Number of subjects: 129
Study 30451891 — intervention group
Group type: EXPERIMENTAL
Intervention: Stannous fluoride products
Number of subjects: 54
Study 27192639 — intervention group
Group type: EXPERIMENTAL
Intervention: Simultaneous third molar extraction during orthognathic surgery
Number of subjects: 100
Study 27192639 — intervention group
Group type: COMPARATOR
Intervention: Prior extraction of third molars before orthognathic surgery
Number of subjects: 100
Study 24982490 — intervention group
Group type: EXPERIMENTAL
Intervention: Smartphone application
Number of subjects: 90
Study 24982490 — intervention group
Group type: COMPARATOR
Intervention: Control group (no smartphone application)
Number of subjects: 90
Study 22393101 — intervention group
Group type: COMPARATOR
Intervention: Tamoxifen
Number of subjects: 732
Study 21097734 — intervention group
Group type: EXPERIMENTAL
Intervention: FOYC plus one of two brief parent interventions
Number of subjects: 1360
Study 21097734 — intervention group
Group type: COMPARATOR
Intervention: Control condition 'Wondrous Wetlands' plus a brief parent intervention
Number of subjects: 1360
Study 19004914 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% ropivacaine (ON-Q group)
Number of subjects: 168
Study 19004914 — intervention group
Group type: COMPARATOR
Intervention: 0.9% NaCl (control group)
Number of subjects: 168
Study 16487032 — intervention group
Group type: EXPERIMENTAL
Intervention: IFN alone
Number of subjects: 22
Study 16487032 — intervention group
Group type: EXPERIMENTAL
Intervention: IFN in combination with amantadine or ribavirin
Number of subjects: 22
Study 16487032 — intervention group
Group type: COMPARATOR
Intervention: Baseline
Number of subjects: 22
Study 14761489 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood transfusion and scopolamine injection in addition to traditional therapy (gastrolavage, purgation, redox agent)
Number of subjects: 400
Study 14761489 — intervention group
Group type: COMPARATOR
Intervention: Traditional combined therapy (gastrolavage, purgation, redox agent)
Number of subjects: 400
Study 10921566 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional support with 15% fat and 50% fish oil (Group III)
Number of subjects: 23
Study 10921566 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional support with 15% fat (Group II)
Number of subjects: 23
Study 10921566 — intervention group
Group type: COMPARATOR
Intervention: Nutritional support with 35% fat (Group I, control)
Number of subjects: 23
Study 10921566 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 23
Study 8970901 — intervention group
Group type: EXPERIMENTAL
Intervention: Free and total Pyr and Dpyr in serum
Number of subjects: 38
Study 8970901 — intervention group
Group type: EXPERIMENTAL
Intervention: Free serum levels of Pyr and Dpyr
Number of subjects: 38
Study 8970901 — intervention group
Group type: EXPERIMENTAL
Intervention: Renal clearance of free cross-link fraction
Number of subjects: 38
Study 8970901 — intervention group
Group type: EXPERIMENTAL
Intervention: Fractional clearance of free fraction
Number of subjects: 38
Study 8970901 — intervention group
Group type: EXPERIMENTAL
Intervention: Fractional clearance of conjugated fraction
Number of subjects: 38
Study 8970901 — intervention group
Group type: EXPERIMENTAL
Intervention: Fractional excretion of free Dpyr
Number of subjects: 38
Study 1452618 — intervention group
Group type: EXPERIMENTAL
Intervention: High-performance liquid chromatographic method with o-phthaldialdehyde precolumn derivatization
Number of subjects: 0
Study 6697676 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefazolin 20 mg/kg i.v. administered with anesthesia
Number of subjects: 40
Study 6697676 — intervention group
Group type: COMPARATOR
Intervention: Cefazolin 20 mg/kg i.v. administered 'on call'
Number of subjects: 40
Study 6697676 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefoxitin 30 mg/kg i.v. administered with anesthesia
Number of subjects: 40
Study 6697676 — intervention group
Group type: COMPARATOR
Intervention: Cefoxitin 30 mg/kg i.v. administered 'on call'
Number of subjects: 40
Study 31713391 — intervention group
Group type: EXPERIMENTAL
Intervention: Laboratory technicians' reading ability evaluation
Number of subjects: 869
Study 31713391 — intervention group
Group type: EXPERIMENTAL
Intervention: Evaluation of coating, dyeing and clean quality of blood slides
Number of subjects: 869
Study 31713391 — intervention group
Group type: EXPERIMENTAL
Intervention: Evaluation of mixed infections reading ability
Number of subjects: 869
Study 31713391 — intervention group
Group type: COMPARATOR
Intervention: Comparison of reading abilities among different hospital types
Number of subjects: 869
Study 31713391 — intervention group
Group type: COMPARATOR
Intervention: Comparison of reading abilities among different administrative levels
Number of subjects: 869
Study 29102648 — intervention group
Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 637
Study 29102648 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiation alone
Number of subjects: 637
Study 29102648 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic therapy alone
Number of subjects: 637
Study 29102648 — intervention group
Group type: EXPERIMENTAL
Intervention: Both radiation and systemic therapy
Number of subjects: 637
Study 29102648 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic therapy with radiation
Number of subjects: 637
Study 27323955 — intervention group
Group type: EXPERIMENTAL
Intervention: Autonomous condition (qualitatively trained researchers)
Number of subjects: 2552
Study 27323955 — intervention group
Group type: COMPARATOR
Intervention: Assisted condition (OPO hospital development staff)
Number of subjects: 2552
Study 24559003 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus casei shirota (LcS) at a dose of 16 x 10(9) CFU
Number of subjects: 30
Study 24559003 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus casei shirota (LcS) at a dose of 8 x 10(9) CFU
Number of subjects: 30
Study 24559003 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 30
Study 22118417 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexeryl (an emollient cream containing glycerol 15% and paraffin 10%)
Number of subjects: 0
Study 22118417 — intervention group
Group type: COMPARATOR
Intervention: Placebo (its vehicle)
Number of subjects: 0
Study 22118417 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexeryl
Number of subjects: 0
Study 22118417 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 22118417 — intervention group
Group type: COMPARATOR
Intervention: Vehicle (previously treated group)
Number of subjects: 0
Study 22118417 — intervention group
Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 0
Study 20616762 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-dose group (reduced 5-component acellular pertussis vaccine combined with tetanus toxoid and reduced diphtheria toxoid)
Number of subjects: 214
Study 20616762 — intervention group
Group type: COMPARATOR
Intervention: 5-dose group (Tdap vaccine)
Number of subjects: 214
Study 18356793 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrostimulation of acupuncture points (LI4, ST36, HT7, LR3) for 20 minutes every hour for 12 hours
Number of subjects: 12
Study 18356793 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrostimulation of acupuncture points
Number of subjects: 12
Study 16022607 — intervention group
Group type: EXPERIMENTAL
Intervention: WHO technique
Number of subjects: 375
Study 16022607 — intervention group
Group type: COMPARATOR
Intervention: Australian technique
Number of subjects: 375
Study 16022607 — intervention group
Group type: COMPARATOR
Intervention: US technique
Number of subjects: 375
Study 11827924 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiarrhythmic drugs (AAD)
Number of subjects: 800
Study 11827924 — intervention group
Group type: COMPARATOR
Intervention: Implantable cardioverter defibrillator (ICD)
Number of subjects: 800
Study 11827924 — intervention group
Group type: COMPARATOR
Intervention: ICD
Number of subjects: 800
Study 11827924 — intervention group
Group type: COMPARATOR
Intervention: AAD
Number of subjects: 800
Study 9915320 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.025 mg/kg etomidate
Number of subjects: 104
Study 9915320 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.050 mg/kg etomidate
Number of subjects: 104
Study 9915320 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.075 mg/kg etomidate
Number of subjects: 104
Study 9915320 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.100 mg/kg etomidate
Number of subjects: 104
Study 9915320 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.200 mg/kg etomidate
Number of subjects: 104
Study 9915320 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.300 mg/kg etomidate
Number of subjects: 104
Study 9915320 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.050 mg/kg etomidate (pretreatment)
Number of subjects: 104
Study 9915320 — intervention group
Group type: COMPARATOR
Intervention: Placebo (pretreatment)
Number of subjects: 104
Study 9915320 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.030 mg/kg etomidate (pretreatment)
Number of subjects: 104
Study 9915320 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.075 mg/kg etomidate (pretreatment)
Number of subjects: 104
Study 7751875 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-agent bolus 5-FU
Number of subjects: 620
Study 7751875 — intervention group
Group type: EXPERIMENTAL
Intervention: Unmodulated infusion regimens
Number of subjects: 620
Study 7751875 — intervention group
Group type: COMPARATOR
Intervention: 5-FU bolus therapy
Number of subjects: 620
Study 7751875 — intervention group
Group type: COMPARATOR
Intervention: 5-FU bolus arms
Number of subjects: 620
Study 7751875 — intervention group
Group type: EXPERIMENTAL
Intervention: Entire cohort
Number of subjects: 620
Study 2261951 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose ara-C in combination with 13-cis-retinoic acid (13-CRA) and 1 alpha-hydroxy-vitamin D3 (1 alpha D3)
Number of subjects: 63
Study 2261951 — intervention group
Group type: COMPARATOR
Intervention: Low-dose ara-C (arm A)
Number of subjects: 63
Study 6108606 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol
Number of subjects: 7
Study 6108606 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 7
Study 6108606 — intervention group
Group type: COMPARATOR
Intervention: Control (no drug)
Number of subjects: 7
Study 30820319 — intervention group
Group type: EXPERIMENTAL
Intervention: FBH+ (Full Birth History with additional questions on pregnancy losses in the past 5 years)
Number of subjects: 68000
Study 30820319 — intervention group
Group type: COMPARATOR
Intervention: FPH (Full Pregnancy History)
Number of subjects: 68000
Study 28292270 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal ranibizumab (IVR)
Number of subjects: 14
Study 26041848 — intervention group
Group type: EXPERIMENTAL
Intervention: FX006 (10 mg)
Number of subjects: 228
Study 26041848 — intervention group
Group type: EXPERIMENTAL
Intervention: FX006 (40 mg)
Number of subjects: 228
Study 26041848 — intervention group
Group type: EXPERIMENTAL
Intervention: FX006 (60 mg)
Number of subjects: 228
Study 26041848 — intervention group
Group type: COMPARATOR
Intervention: Immediate-release triamcinolone acetonide (40 mg)
Number of subjects: 228
Study 23534896 — intervention group
Group type: EXPERIMENTAL
Intervention: Fexofenadine 240 mg/day
Number of subjects: 0
Study 23534896 — intervention group
Group type: COMPARATOR
Intervention: Fexofenadine 120 mg/day
Number of subjects: 0
Study 20085851 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosuvastatin (26 weeks)
Number of subjects: 69
Study 20085851 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 69
Study 19164608 — intervention group
Group type: EXPERIMENTAL
Intervention: HMB/Arg/Lys supplement (beta-hydroxy-beta-methylbutyrate, L-arginine, and L-lysine)
Number of subjects: 77
Study 19164608 — intervention group
Group type: COMPARATOR
Intervention: Control supplement (isonitrogenous)
Number of subjects: 77
Study 17210383 — intervention group
Group type: EXPERIMENTAL
Intervention: Best medical therapy (BMT) plus supervised exercise
Number of subjects: 34
Study 17210383 — intervention group
Group type: EXPERIMENTAL
Intervention: Best medical therapy (BMT) plus cilostazol
Number of subjects: 34
Study 17210383 — intervention group
Group type: EXPERIMENTAL
Intervention: Best medical therapy (BMT) plus supervised exercise plus cilostazol
Number of subjects: 34
Study 17210383 — intervention group
Group type: COMPARATOR
Intervention: Best medical therapy (BMT) alone
Number of subjects: 34
Study 16338562 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytochrome c peroxidase eyedrops (3 times a day for 1 week or until corneal reepithelialization was completed)
Number of subjects: 36
Study 16338562 — intervention group
Group type: COMPARATOR
Intervention: Placebo (standard postoperative therapy)
Number of subjects: 36
Study 12389073 — intervention group
Group type: EXPERIMENTAL
Intervention: Grapefruit juice pretreatment
Number of subjects: 6
Study 12389073 — intervention group
Group type: COMPARATOR
Intervention: Oral etoposide without grapefruit juice
Number of subjects: 6
Study 12389073 — intervention group
Group type: COMPARATOR
Intervention: IV etoposide
Number of subjects: 6
Study 9887419 — intervention group
Group type: EXPERIMENTAL
Intervention: Multifaceted bicycle helmet promotion program including classroom activities, parent education, helmet fitting and distribution, bicycle skills and safety event, and helmet requirement on school grounds.
Number of subjects: 880
Study 9887419 — intervention group
Group type: COMPARATOR
Intervention: Control group with no helmet promotion activities.
Number of subjects: 880
Study 8665721 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal lysine aspirin (2000 micrograms)
Number of subjects: 20
Study 8665721 — intervention group
Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 20
Study 2223348 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl 15 micrograms kg‐1 i.v. before surgery
Number of subjects: 2
Study 2223348 — intervention group
Group type: COMPARATOR
Intervention: Fentanyl 15 micrograms kg‐1 i.v. with corticotrophin releasing factor 100 micrograms i.v., growth hormone releasing hormone 100 micrograms i.v., and arginine vasopressin 10 units i.m.
Number of subjects: 2
Study 2223348 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl 15 micrograms kg‐1 i.v. with releasing factors
Number of subjects: 2
Study 543907 — intervention group
Group type: EXPERIMENTAL
Intervention: mezlocillin
Number of subjects: 50
Study 543907 — intervention group
Group type: EXPERIMENTAL
Intervention: mezlocillin (slow injection)
Number of subjects: 50
Study 543907 — intervention group
Group type: COMPARATOR
Intervention: ampicillin
Number of subjects: 50
Study 30375661 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive‐intermittent music therapy (4x/week, off, 4x/week, off)
Number of subjects: 24
Study 30375661 — intervention group
Group type: COMPARATOR
Intervention: Standard spaced protocolised music therapy (2x/week)
Number of subjects: 24
Study 28800385 — intervention group
Group type: EXPERIMENTAL
Intervention: New paediatric valaciclovir formulation
Number of subjects: 20
Study 28800385 — intervention group
Group type: COMPARATOR
Intervention: Reference formulation (crushed and suspended tablets)
Number of subjects: 20
Study 25727104 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.015% ingenol mebutate gel (IMB) applied daily for three consecutive days
Number of subjects: 100
Study 25727104 — intervention group
Group type: COMPARATOR
Intervention: 5% 5-fluorouracil (5-FU) cream applied twice a day for 4 weeks
Number of subjects: 100
Study 23859934 — intervention group
Group type: EXPERIMENTAL
Intervention: 8-week group motivational intervention
Number of subjects: 69
Study 23859934 — intervention group
Group type: COMPARATOR
Intervention: Biweekly newsletters by mail (Control)
Number of subjects: 69
Study 20797441 — intervention group
Group type: EXPERIMENTAL
Intervention: Anticipatory mental imagery of a mildly fearful face
Number of subjects: 0
Study 20797441 — intervention group
Group type: EXPERIMENTAL
Intervention: Anticipatory mental imagery
Number of subjects: 0
Study 20066950 — intervention group
Group type: EXPERIMENTAL
Intervention: Thoracic irradiation
Number of subjects: 0
Study 20066950 — intervention group
Group type: COMPARATOR
Intervention: Innovative radiation technology
Number of subjects: 0
Study 16765271 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment acceptability and effect among compliers
Number of subjects: 5
Study 16765271 — intervention group
Group type: EXPERIMENTAL
Intervention: Preference-based analysis
Number of subjects: 5
Study 15636216 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical 0.5% betaxolol
Number of subjects: 114
Study 15636216 — intervention group
Group type: COMPARATOR
Intervention: Artificial tears
Number of subjects: 114
Study 11078488 — intervention group
Group type: EXPERIMENTAL
Intervention: Anastrozole 1 mg once daily
Number of subjects: 353
Study 11078488 — intervention group
Group type: COMPARATOR
Intervention: Tamoxifen 20 mg once daily
Number of subjects: 353
Study 7503497 — intervention group
Group type: EXPERIMENTAL
Intervention: Acyclovir, 400 mg twice daily for 70 days
Number of subjects: 34
Study 7503497 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study 1857729 — intervention group
Group type: EXPERIMENTAL
Intervention: Ventoline inhalation aerosol
Number of subjects: 0
Study 1857729 — intervention group
Group type: EXPERIMENTAL
Intervention: Orion salbutamol inhalation aerosol
Number of subjects: 0
Study 1857729 — intervention group
Group type: COMPARATOR
Intervention: Both salbutamol aerosols
Number of subjects: 0
Study 6409917 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipodate (3 g on days 1 and 5 of fasting)
Number of subjects: 24
Study 6409917 — intervention group
Group type: EXPERIMENTAL
Intervention: T3 (5 μg every 4 h)
Number of subjects: 24
Study 6409917 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipodate plus T3
Number of subjects: 24